Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

 Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Roche Collaborates with Atea Pharmaceuticals to Develop AT-527 for COVID-19

Shots:

  • The companies will collaborate to develop, manufacture, and distribute AT-527 to combat COVID-19. If approved, Atea will be responsible for distributing the treatment option in the US, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the US
  • The therapy is currently being evaluated in P-II study for hospitalized patients with moderate COVID-19 with anticipated P-III initiation in Q1’21, that explores the potential use in patients outside of the hospital setting. Additionally, AT-527 may be developed for post-exposure prophylactic settings
  • AT-527 is an investigational, oral, purine nucleotide prodrug that has demonstrated in antiviral activity against several enveloped single-stranded RNA virus, including human flavivirus and coronavirus

Click here ­to­ read full press release/ article | Ref: Roche | Image: The Times of Israel

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post